Novo Nordisk licensed a clinical-stage MASP-3 inhibitor from Omeros. Omeros is eligible to receive $340 million upfront, royalties, and up to $2.1 billion in milestone payments. Omeros' cash balance ...

LONDON/COPENHAGEN, Oct 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, as the obesity drugmaker faces ...

Under the terms of the agreement, Novo Nordisk will obtain exclusive global rights to develop and commercialize zaltenibart across all indications. Omeros is set to receive $340 million in upfront and ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

NEW YORK (AP) — Armed with hundreds of thousands of dollars from Newman’s Own Foundation and Ozempic creator Novo Nordisk, young Native Americans are leading the fight against persistently high rates ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues. The ...

starts at Rs. 99,999 which is Rs. 54,099 costlier than base model of at Rs. 45,900. In technical specifications, . Komaki FAM 1.0 is available in 1 different colours while Zelo Zoop comes with 4 ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket. The price cut ...

Stay up-to-date on Novo Nordisk A/S Common Stock (NVO) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule.